NCT04599556

Clinical Trial for the Safety and Efficacy of Anti-CD7 CAR-T Cell Therapy for Patients With Relapsed or Refractory CD7 Positive Hematological Malignancy

Clinical Trial for the Safety and Efficacy of Anti-CD7 Chimeric Antigen Receptor Cell Therapy for Patients With Relapsed or Refractory CD7 Positive Hematological Malignancy

• Status: Unknown
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 81 (estimated)
• Sponsor: Zhejiang University · Academic / Other
• Sex: All
• Age: 3 Years – 80 Years
• Healthy volunteers: Not accepted

Summary

This is a prospective, open-label, single-center clinical trial. This study will evaluate the safety and efficacy of anti-CD7 CAR-T cells in the treatment of relapsed or refractory CD7 positive T-ALL/LBL, T-NHL and AML. The primary endpoints are dose limiting toxicity (DLT) and the incidence of treatment emergent adverse event (TEAE).

Conditions

• CD7+ Acute Leukemia
• CD7+ Lymphoma

Interventions

Type	Name	Description
BIOLOGICAL	anti-CD7 CAR-T	Lymphodepleting chemotherapy followed by anti-CD7 CAR-T infusion

Timeline

• Start date: 2021-04-01
• Primary completion: 2023-12-30
• Completion: 2025-12-30
• First posted: 2020-10-22
• Last updated: 2023-12-06

Locations

1 site across 1 country: China